|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
ATE254136T1
(de)
*
|
1994-07-20 |
2003-11-15 |
Gen Hospital Corp |
Interaktions-fullensysteme zum nachweis von protein-interaktionen
|
|
EP0830459B1
(de)
|
1995-04-11 |
2007-01-24 |
The General Hospital Corporation |
Reverse "two-hybrid"-systeme
|
|
WO1997041255A1
(en)
*
|
1996-04-26 |
1997-11-06 |
Massachusetts Institute Of Technology |
Three-hybrid screening assay
|
|
EP1241265A3
(de)
*
|
1996-04-26 |
2004-02-18 |
Massachusetts Institute Of Technology |
Screening-Verfahren für kleine Liganden
|
|
US5776689A
(en)
*
|
1996-07-19 |
1998-07-07 |
The Regents Of The University Of California |
Protein recruitment system
|
|
US5807708A
(en)
*
|
1996-07-30 |
1998-09-15 |
Millennium Pharmaceuticals, Inc. |
Conservin nucleic acid molecules and compositions
|
|
US5846722A
(en)
*
|
1996-10-16 |
1998-12-08 |
Terrapin Technologies, Inc. |
System to detect small molecule/peptide interaction
|
|
US6365347B1
(en)
*
|
1997-04-11 |
2002-04-02 |
The Regents Of The University Of California |
Method for identifying disruptors of biological pathways using genetic selection
|
|
EP1040201A4
(de)
*
|
1997-11-28 |
2001-11-21 |
Invitrogen Corp |
Einkettige monoklonal-antikörper-fusions-agentien die die in vivo transkription regulieren
|
|
EP1035207A1
(de)
*
|
1999-03-09 |
2000-09-13 |
MultiGene Biotech GmbH |
cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
|
|
EP2365081A3
(de)
|
1999-04-12 |
2012-07-18 |
Agensys, Inc. |
13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
|
|
EP1792989A1
(de)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
|
|
EP1198586B1
(de)
*
|
1999-06-26 |
2010-03-03 |
Odyssey Thera, Inc. |
Eine in vivo "bibliothek-gegen-bibliothek-selektion" von optimierten protein-protein-wechselwirkungen
|
|
US6602501B1
(en)
|
1999-08-12 |
2003-08-05 |
Agensys, Inc. |
C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
|
|
ES2316387T3
(es)
|
1999-10-05 |
2009-04-16 |
Agensys, Inc. |
Receptor acoplado a proteina g sobrexpresado en cancer de prostata y la utilizacion del mismo.
|
|
US6893818B1
(en)
*
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
|
US20030211495A1
(en)
*
|
2000-03-08 |
2003-11-13 |
Richard Hopkins |
Reverse n-hybrid screening method
|
|
JP2004511219A
(ja)
|
2000-07-12 |
2004-04-15 |
アジェンシス,インコーポレイテッド |
膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原
|
|
PT1313850E
(pt)
|
2000-08-28 |
2008-11-18 |
Agensys Inc |
Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro
|
|
EP1317278B1
(de)
*
|
2000-09-11 |
2009-11-11 |
Dana-Farber Cancer Institute, Inc. |
Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
|
|
CA2425208C
(en)
|
2000-09-26 |
2013-04-09 |
Duke University |
Rna aptamers and methods for identifying the same
|
|
WO2002058450A2
(en)
*
|
2000-12-22 |
2002-08-01 |
Dana-Faber Cancer Institute, Inc. |
Regulation of cell growth by muc1
|
|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Rgmおよびそのモジュレーターの用途
|
|
CA2439263C
(en)
|
2001-03-02 |
2012-10-23 |
Frank Becker |
Three hybrid assay system
|
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
EP2280030A3
(de)
|
2001-04-10 |
2011-06-15 |
Agensys, Inc. |
Nukleinsäuren und zugehörige Proteine für die Behandlung und den Nachweis von Krebs
|
|
EP2364990A1
(de)
*
|
2001-05-25 |
2011-09-14 |
Duke University |
Modulatoren von pharmakologischen Wirkstoffen
|
|
JP2005505271A
(ja)
|
2001-09-06 |
2005-02-24 |
アジェンシス, インコーポレイテッド |
癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質
|
|
US20040049024A1
(en)
*
|
2001-12-07 |
2004-03-11 |
Geoff Clark |
Compositions and methods related to the minn1 tumor suppressor gene and protein
|
|
US20040086945A1
(en)
*
|
2002-06-03 |
2004-05-06 |
The Procter & Gamble Company |
Hairless protein-interacting partner complexes and methods thereto
|
|
WO2004003150A2
(en)
*
|
2002-06-26 |
2004-01-08 |
Yale University |
Modulators and modulation of the interacton between rgm and neogenin
|
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
|
US20060099713A1
(en)
*
|
2002-10-01 |
2006-05-11 |
Buck Institute |
Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
|
|
CA2515699C
(en)
|
2003-02-10 |
2015-01-27 |
Aya Jakobovits |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
|
US20080090770A1
(en)
*
|
2003-04-11 |
2008-04-17 |
Belmares Michael P |
Modulation of Muc1 Mediated Signal Transduction
|
|
EP2319524B1
(de)
|
2003-05-30 |
2013-08-21 |
Agensys, Inc. |
Prostatstammzellenantigen-Varianten und Untersequenzen davon
|
|
GB0315248D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Hoffmann La Roche |
HCV regulated protein expression
|
|
US8129506B2
(en)
|
2003-10-24 |
2012-03-06 |
Genzyme Corporation |
Modulation of the interaction of MUC1 with MUC1 ligands
|
|
EP1533619B1
(de)
|
2003-11-20 |
2009-04-29 |
F. Hoffmann-Roche AG |
Spezifische Marker für Stoffwechselssyndrome
|
|
EP1718367A1
(de)
*
|
2004-02-23 |
2006-11-08 |
Genzyme Corporation |
Muc1-antagonisten-verstärkung von durch todes-rezeptor-ligand ausgelöster apoptose
|
|
ES2494940T3
(es)
|
2004-04-22 |
2014-09-16 |
Regado Biosciences, Inc. |
Moduladores de factores de coagulación mejorados
|
|
WO2005118864A2
(en)
|
2004-05-28 |
2005-12-15 |
Agensys, Inc. |
Antibodies and related molecules that bind to psca proteins
|
|
US8034553B2
(en)
|
2004-06-24 |
2011-10-11 |
Kimberly-Clark Worldwide, Inc. |
Biomarkers for wound healing
|
|
EP2444099A1
(de)
|
2005-03-31 |
2012-04-25 |
Agensys, Inc. |
An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
|
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
|
US9243243B2
(en)
|
2006-08-31 |
2016-01-26 |
Nexigen Gmbh |
Means and methods for detecting protein-peptide interactions
|
|
EP1927364A1
(de)
*
|
2006-12-01 |
2008-06-04 |
Ecole Normale Superieure De Lyon |
Polypetitde mit modulatorischer Wirkung auf Zellen
|
|
WO2008097844A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Dana -Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
|
|
US7972870B2
(en)
|
2007-02-02 |
2011-07-05 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
|
|
EP2034020A1
(de)
*
|
2007-08-30 |
2009-03-11 |
Procomcure Biotech GmbH |
Verfahren zur Herstellung eines modifizierten Peptids
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2101173A1
(de)
*
|
2008-03-14 |
2009-09-16 |
Vivalis |
In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist
|
|
JP2011521411A
(ja)
*
|
2008-05-15 |
2011-07-21 |
コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ |
X線ビームを生成する方法及びシステム
|
|
JP2013507950A
(ja)
|
2009-10-22 |
2013-03-07 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク |
グアニン交換因子インヒビター及び抗癌剤としてのその使用
|
|
JP5951498B2
(ja)
|
2009-12-08 |
2016-07-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
網膜神経線維層変性の治療に使用するためのrgmaタンパク質に対するモノクローナル抗体
|
|
WO2011083147A1
(en)
|
2010-01-08 |
2011-07-14 |
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh |
Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
|
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
US20130330347A1
(en)
|
2012-01-27 |
2013-12-12 |
Abbvie Inc. |
Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
ES2897707T3
(es)
|
2014-12-24 |
2022-03-02 |
Neximmune Inc |
Composiciones de nanopartículas y procedimientos para la inmunoterapia
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
CN108883150A
(zh)
|
2015-11-19 |
2018-11-23 |
阿斯克雷佩西治疗公司 |
具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
|
|
JP6991979B2
(ja)
|
2016-02-05 |
2022-03-04 |
オリオニス バイオサイエンシズ ビーブイ |
Cd8結合物質
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
EP3455245A2
(de)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutisches targeting von nichtzellulären strukturen
|
|
CA3023883A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
AU2017339970A1
(en)
|
2016-10-04 |
2019-04-18 |
Asclepix Therapeutics, Llc |
Compounds and methods for activating Tie2 signaling
|
|
CN110114368B
(zh)
|
2016-10-24 |
2024-08-02 |
奥睿尼斯生物科学私人有限公司 |
靶向突变干扰素-γ及其用途
|
|
EP3576765B1
(de)
|
2017-02-06 |
2025-07-16 |
Orionis Biosciences, Inc. |
Zielgerichtetes manipuliertes interferon und verwendungen davon
|
|
WO2018141964A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
WO2019028427A1
(en)
|
2017-08-03 |
2019-02-07 |
Asclepix Therapeutics, Llc. |
METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
|
|
US12059476B2
(en)
|
2017-10-10 |
2024-08-13 |
The Johns Hopkins University |
Biodegradable biomimetic particles
|
|
GB2584211B
(en)
|
2017-11-16 |
2023-05-24 |
Synthex Inc |
Selective modulation of protein-protein interactions
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
EP3890773A4
(de)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
Modulation von dendritischen zelllinien
|
|
WO2020168059A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
|
WO2020168024A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
CN114127298B
(zh)
|
2019-05-15 |
2025-09-02 |
辛赛克斯公司 |
蛋白质的选择性降解
|
|
JP7727628B2
(ja)
|
2019-12-03 |
2025-08-21 |
アラマー バイオサイエンシーズ, インク. |
核酸結合免疫サンドイッチアッセイ(nulisa)
|
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
|
US20220267451A1
(en)
|
2020-10-14 |
2022-08-25 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
TW202320850A
(zh)
|
2021-08-10 |
2023-06-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物、劑量及方法
|
|
EP4551600A1
(de)
|
2022-07-04 |
2025-05-14 |
Vib Vzw |
Blut-cerebrospinal-fluidbarriere-überkreuzende antikörper
|
|
US20240228620A1
(en)
|
2022-10-06 |
2024-07-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
IL319951A
(en)
|
2022-11-30 |
2025-05-01 |
Integral Molecular Inc |
Antibodies targeting claudin 6, including its bispecific formats
|
|
EP4688849A1
(de)
|
2023-04-03 |
2026-02-11 |
Vib Vzw |
Blut-hirn-schranken-überkreuzende antikörper
|
|
WO2025014773A1
(en)
|
2023-07-07 |
2025-01-16 |
Viridian Therapeutics, Inc. |
Methods of treating chronic thyroid eye disease
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
TW202535948A
(zh)
|
2023-12-17 |
2025-09-16 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物、劑量及方法
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
US20260015407A1
(en)
|
2024-07-15 |
2026-01-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory fusion proteins and related methods
|